Literature DB >> 18305316

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.

Vincenzo Panichi1, Giovanni M Rizza, Sabrina Paoletti, Roberto Bigazzi, Mauro Aloisi, Giuliano Barsotti, Paolo Rindi, Giacli' Donati, Alessandro Antonelli, Erica Panicucci, Gianni Tripepi, Ciro Tetta, Roberto Palla.   

Abstract

BACKGROUND: The 'RISchio CArdiovascolare nei pazienti afferenti all' Area Vasta In Dialisi' (RISCAVID) study is an observational and prospective trial including the whole chronic haemodialysis (HD) population in the northwest part of Tuscany (1.235 million people). The aim of the study was to elucidate the relevance of traditional and non-traditional risk factors of mortality and morbidity in HD patients as well as the impact of different HD modalities.
METHODS: A total of 757 HD patients (mean age 66 +/- 14 years, mean dialytic age 70 +/- 76 months, diabetes 19%) were prospectively followed up for 30 months and all-cause mortality, cardiovascular (CV) mortality and non-fatal CV events (acute myocardial infarction and stroke) were registered. At the time of the enrolment, demographic, clinical and laboratory data of the whole population were entered into a centralized database. Serum albumin, high-sensitive C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) were centrally determined at the start of the study. Patients were stratified into three groups according to the HD modality: standard bicarbonate HD (BHD) (n = 424), haemodiafiltration (HDF) with sterile bags (n = 204) and online HDF (n = 129). The Cox proportional hazards regression assessed adjusted differences in CV morbidity and mortality risk; a multivariate analysis was also performed.
RESULTS: All-cause and CV mortality was 12.9%/year and 5.9%/year, respectively. Patients with combined high levels of CRP and pro-inflammatory cytokines showed an increased risk for CV (RR 1.9, P < 0.001) and all-cause mortality (RR 2.57, P < 0.001). Multivariate analysis adjusted for comorbidity and demographic showed CRP as the most powerful mortality predictor (P < 0.001) followed by IL-6. The Cox proportional hazards regression assessed that online HDF and HDF patients had a significantly increased adjusted cumulative survival than BHD (P < 0.01).
CONCLUSIONS: Data at 30 months from this study showed the synergic effect of CRP and pro-inflammatory cytokines as the strong predictors of all-cause and CV mortality. HDF was associated with an improved cumulative survival independent of the dialysis dose.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305316     DOI: 10.1093/ndt/gfm951

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  48 in total

1.  Hemodiafiltration to Address Unmet Medical Needs ESKD Patients.

Authors:  Bernard Canaud; Jörg Vienken; Stephen Ash; Richard A Ward
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-06       Impact factor: 8.237

2.  Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes.

Authors:  Muriel P C Grooteman; Marinus A van den Dorpel; Michiel L Bots; E Lars Penne; Neelke C van der Weerd; Albert H A Mazairac; Claire H den Hoedt; Ingeborg van der Tweel; Renée Lévesque; Menso J Nubé; Piet M ter Wee; Peter J Blankestijn
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

3.  The uremic solute-AHR-tissue factor axis in vascular cells, mouse models and thrombosis in chronic kidney disease patients.

Authors:  Nigel Mackman; Jonathan H Erlich
Journal:  Ann Transl Med       Date:  2018-06

4.  High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients.

Authors:  Francisco Maduell; Francesc Moreso; Mercedes Pons; Rosa Ramos; Josep Mora-Macià; Jordi Carreras; Jordi Soler; Ferran Torres; Josep M Campistol; Alberto Martinez-Castelao
Journal:  J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 10.121

Review 5.  Antiplatelet agents in hemodialysis.

Authors:  Massimiliano Migliori; Vincenzo Cantaluppi; Alessia Scatena; Vincenzo Panichi
Journal:  J Nephrol       Date:  2016-12-08       Impact factor: 3.902

Review 6.  Why choose high volume online post-dilution hemodiafiltration?

Authors:  Carlo Basile; Andrew Davenport; Peter J Blankestijn
Journal:  J Nephrol       Date:  2016-09-01       Impact factor: 3.902

7.  Survival of incident patients on high-volume online hemodiafiltration compared to low-volume online hemodiafiltration and high-flux hemodialysis.

Authors:  Goran Imamović; Rajko Hrvačević; Sonja Kapun; Daniele Marcelli; Inga Bayh; Aileen Grassmann; Laura Scatizzi; Jelena Maslovarić; Bernard Canaud
Journal:  Int Urol Nephrol       Date:  2013-09-21       Impact factor: 2.370

Review 8.  Water quality in conventional and home haemodialysis.

Authors:  Matthew J Damasiewicz; Kevan R Polkinghorne; Peter G Kerr
Journal:  Nat Rev Nephrol       Date:  2012-10-23       Impact factor: 28.314

9.  Geriatric nutritional risk index is a strong predictor of mortality in hemodialysis patients: data from the Riscavid cohort.

Authors:  Vincenzo Panichi; Adamasco Cupisti; Alberto Rosati; Adriana Di Giorgio; Alessia Scatena; Ophelia Menconi; Laura Bozzoli; Anna Bottai
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

10.  Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients.

Authors:  E Lars Penne; Neelke C van der Weerd; Peter J Blankestijn; Marinus A van den Dorpel; Muriel P C Grooteman; Menso J Nubé; Piet M Ter Wee; Renée Lévesque; Michiel L Bots
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-12       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.